Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Identification of bioactive molecules that target acute myeloid leukemia stem cells

FY 2016-17

Summary
Acute myeloid leukemia (AML) is an aggressive form of blood cancer characterized by the uncontrolled expansion of the number of myeloid white blood cells. When left untreated, this can ultimately lead to death by uncontrolled bleeding or infection. The disease can be forced into remission by using very aggressive treatments such as chemotherapy or stem cell transplants. Unfortunately, many patients relapse and succumb to the disease resulting in a poor 5-year survival rate of approximately 30% in adult patients. Relapse is thought to be caused by unique cells called leukemic stem cells (LSCs). These LSCs are often resistant to the standard treatment because they do not reproduce extensively; the trait of cancer cells that chemotherapies typically target. In addition, these cells have the ability to turn into all the various cancer cells found in an AML patient and thus if left unattended can completely restore the disease. Therefore, it is clear that a successful therapy would need to target and destroy all LSCs to more effectively prevent relapse and cure a higher proportion of AML patients. We hypothesize that we will be able to identify drugs that specifically target LSCs in AML by screening molecules predicted by computational analysis to be harmful to LSCs. Through this method we have already identified 152 drugs and through further screening found 12 drugs that target the LSCs without harming the healthy blood stem cells. We hope to further characterize and understand the effects of these drugs against AML samples as well as test them in animal models of AML. The identification of drugs that can eliminate these therapy-resistant LSCs will result in the development of novel therapies that can eventually lead to improved survival in AML patients.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
365480
Name
Boileau Meaghan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Identification of bioactive molecules that target acute myeloid leukemia stem cells
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Bioinformatics; Drug Screen; Flow Cytometry; Leukemic Stem Cells; Xenotransplantation
Abstract
Acute myeloid leukemia (AML) is an aggressive form of blood cancer characterized by the uncontrolled expansion of the number of myeloid white blood cells. When left untreated, this can ultimately lead to death by uncontrolled bleeding or infection. The disease can be forced into remission by using very aggressive treatments such as chemotherapy or stem cell transplants. Unfortunately, many patients relapse and succumb to the disease resulting in a poor 5-year survival rate of approximately 30% in adult patients. Relapse is thought to be caused by unique cells called leukemic stem cells (LSCs). These LSCs are often resistant to the standard treatment because they do not reproduce extensively; the trait of cancer cells that chemotherapies typically target. In addition, these cells have the ability to turn into all the various cancer cells found in an AML patient and thus if left unattended can completely restore the disease. Therefore, it is clear that a successful therapy would need to target and destroy all LSCs to more effectively prevent relapse and cure a higher proportion of AML patients. We hypothesize that we will be able to identify drugs that specifically target LSCs in AML by screening molecules predicted by computational analysis to be harmful to LSCs. Through this method we have already identified 152 drugs and through further screening found 12 drugs that target the LSCs without harming the healthy blood stem cells. We hope to further characterize and understand the effects of these drugs against AML samples as well as test them in animal models of AML. The identification of drugs that can eliminate these therapy-resistant LSCs will result in the development of novel therapies that can eventually lead to improved survival in AML patients.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Boileau, Meaghan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2016-17) | Canada Spends